BUSINESS
Kyowa to Resume Alfacalcidol Shipments in Mid-Sept.; MHLW Urges Priority for Patients without Alternative Therapies
Kyowa Pharmaceutical Industry will gradually resume its shipments of the active vitamin D3 analog alfacalcidol in mid-September because it has resolved a deviation between the product’s approved manufacturing process and its actual process through the approval of a partial change…
To read the full story
Related Article
BUSINESS
- Nxera Licenses GPCR Program to European VC-Backed Startup
February 13, 2026
- Alfresa Launches Neffy Nasal Spray for Anaphylaxis in Japan
February 13, 2026
- Datroway Filed for 1st-Line TNBC in Japan: Daiichi Sankyo
February 13, 2026
- Teijin Seeks Japan Nod for Ascendis’s GHD Drug
February 13, 2026
- Novo Targets Double-Digit Growth in Japan in 2026, Obesity Access Key
February 12, 2026
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…





